Recent 8-K filings for CCEL

• May 8, 2026, 7:59 PM ET regulatory materiality 0.65 negative item 3.01item 7.01item 9.01 ◈ Listing & Compliance Notices

  NYSE American accepts Cryo-Cell compliance plan; trading continues through Sep 2027

  Received notice of non-compliance on Mar 12, 2026 for stockholders' deficit and net losses in two of three fiscal years ending Nov 30, 2025.

• March 12, 2026, 7:59 PM ET regulatory materiality 0.80 negative item 3.01item 7.01item 9.01 ◈ Listing & Compliance Notices

  Cryo-Cell receives NYSE American delisting notice over stockholders' deficit and net losses

  NYSE American cited stockholders' deficit as of Nov 30, 2025 and net losses in two of three fiscal years ended Nov 30, 2025.

• November 12, 2025, 6:59 PM ET dividend materiality 0.60 negative item 8.01

  Cryo-Cell International suspends Q4 2025 dividend; future payouts uncertain

  Company will not declare a quarterly cash dividend for Q4 fiscal 2025.

• October 23, 2025, 7:59 PM ET debt materiality 0.45 neutral item 1.01item 2.03item 9.01 ◈ Debt Financings

  Cryo-Cell International amends credit agreement; reduces revolver to $8M, extends maturities to 2027/2032

  Fifth Amendment extends RCF maturity to Oct 2027 and Term Loan maturity to Jul 2032.

• September 10, 2025, 7:59 PM ET other material materiality 0.10 neutral item 8.01

  Cryo-Cell sets 2025 annual meeting for Oct 21; record date Sept 15

  Annual Meeting scheduled for October 21, 2025.

• May 22, 2025, 7:59 PM ET litigation materiality 0.85 negative item 1.02

  Duke terminates patent license with Cryo-Cell effective May 17; Cryo-Cell previously sought arbitration

  Duke University terminated Patent and Technology License Agreement effective May 17, 2025, claiming Cryo-Cell breached.

• May 8, 2025, 7:59 PM ET dividend materiality 0.60 negative item 8.01item 9.01

  Cryo-Cell reduces quarterly dividend to $0.15 per share, payable May 30, 2025

  Board declares reduced quarterly cash dividend of $0.15 per share, citing current economic environment and capital allocation alternatives.

• October 31, 2024, 7:59 PM ET other materiality 0.15 neutral item 5.07

  Cryo-Cell International reports annual meeting vote results; all director nominees elected

  Directors David Portnoy, Harold Berger, Mark Portnoy, and Daniel Mizrahi each elected with For votes ranging from 3.6M to 4.1M.

• October 30, 2024, 7:59 PM ET dividend materiality 0.50 positive item 8.01item 9.01

  Cryo-Cell initiates $0.25 quarterly cash dividend, payable Nov 29, 2024

  Quarterly dividend of $0.25 per share declared for common stock.

• October 17, 2024, 7:59 PM ET earnings materiality 0.55 neutral item 2.02item 9.01

  Cryo-Cell Q3 revenue $8.07M, net income $1.05M; strategic review ongoing, spinoff on hold

  Revenue $8.07M vs $7.87M YoY; net income $1.05M ($0.13/diluted) vs $0.68M ($0.08).

• September 17, 2024, 7:59 PM ET other materiality 0.20 neutral item 8.01

  Cryo-Cell sets 2024 annual meeting for Oct 29; record date Sep 20

  Annual Meeting of Stockholders scheduled for October 29, 2024.

• March 26, 2024, 7:59 PM ET other material materiality 0.60 neutral item 7.01item 9.01

  Cryo-Cell plans spin-off of Celle Corp. and explores strategic alternatives including sale

  Board authorized spin-off of newly formed Celle Corp. via stock dividend to Cryo-Cell shareholders.

• October 12, 2023, 7:59 PM ET other materiality 0.15 neutral item 5.07 ◈ Shareholder Votes ×4

  Cryo-Cell International annual meeting: all director nominees elected, auditor ratified

  All four director nominees elected: David Portnoy (3.1M for), Harold Berger (3.1M), Mark Portnoy (3.1M), Daniel Mizrahi (3.2M).

• August 25, 2023, 7:59 PM ET other material materiality 0.10 neutral item 8.01

  Cryo-Cell sets 2023 annual meeting for Oct 10; record date Sept 5

  Annual Meeting date: October 10, 2023. Record date for voting: September 5, 2023.

• March 9, 2023, 6:59 PM ET other material materiality 0.60 neutral item 1.01item 9.01 ◈ Material Agreements ×2

  Cryo-Cell amends Duke license, adds milestone for autism MSC therapy; funds IMPACT study

  Second Amendment removes final license fee payment to Duke; license fee now paid in full.

• December 29, 2022, 6:59 PM ET other materiality 0.45 neutral item 5.02item 9.01

  Cryo-Cell enters new 2-year employment agreements with co-CEOs; base salaries set at $700K and $540K

  David Portnoy base salary $700K; Mark Portnoy base salary $540K; effective Dec 1, 2022.

• October 5, 2022, 7:59 PM ET other materiality 0.15 neutral item 5.07

  Cryo-Cell annual meeting votes: all four directors elected, equity plan approved

  David Portnoy elected with 3.97M for, 2.01M withhold; other directors similarly approved.

• August 23, 2022, 7:59 PM ET dividend materiality 0.55 positive item 8.01

  Cryo-Cell declares $0.90 special cash dividend payable Sept 9, 2022

  One-time special cash dividend of $0.90 per share of common stock declared.

• August 23, 2022, 7:59 PM ET other materiality 0.20 neutral item 8.01

  Cryo-Cell sets 2022 annual meeting for Oct 3; record date Sept 2

  Annual Meeting scheduled October 3, 2022; record date for shareholders is September 2, 2022.

• July 22, 2022, 7:59 PM ET debt materiality 0.45 neutral item 1.01item 2.03

  Cryo-Cell enters $18.96M credit facility with Susser Bank; term loan for NC building purchase

  Revolving credit facility of up to $10M and term loan of $8.96M with Susser Bank.

• March 16, 2022, 7:59 PM ET other material materiality 0.50 positive item 1.01item 8.01item 9.01

  Cryo-Cell buys $11.2M NC facility to launch ExtraVault biorepository service

  Purchase price $11.2M for 56,000 sq ft building under construction in Durham, NC.

• February 24, 2022, 6:59 PM ET earnings materiality 0.65 negative item 2.02item 9.01

  Cryo-Cell reports FY2021 revenue $28.9M (-7% YoY), net income $2.1M (-42% YoY)

  Revenue $28.9M, down 7% from $31.1M; processing/storage fees $28.4M vs $29.5M.

• January 25, 2022, 6:59 PM ET regulatory materiality 0.50 negative item 3.01

  Cryo-Cell receives Nasdaq notice for audit committee non-compliance; cure period until Sept 2022

  Nasdaq notified that audit committee has only 2 independent members, needs 3 per Rule 5605.

• December 15, 2021, 6:59 PM ET leadership materiality 0.10 neutral item 5.02 ◈ executive_change

  Cryo-Cell director Brian Sheehy resigns effective Dec 13, 2021

  Brian Sheehy resigned from the Board on December 13, 2021.

• October 25, 2021, 7:59 PM ET other material materiality 0.15 neutral item 5.07

  Cryo-Cell shareholders elect all five director nominees, ratify auditor, approve say-on-pay

  Harold Berger, David Portnoy, Mark Portnoy, Brian Sheehy, Daniel Mizrahi elected as directors.

• October 15, 2021, 7:59 PM ET earnings materiality 0.55 neutral item 2.02item 9.01

  Cryo-Cell Q3 2021 revenue down 8% to $7.5M; net income $857K

  Revenue $7.5M vs $8.1M YoY; processing/storage fees $7.3M, public banking $159K.

• September 22, 2021, 7:59 PM ET leadership materiality 0.45 neutral item 5.02item 8.01item 9.01 ◈ executive_change ×4

  Cryo-Cell appoints co-CEO Portnoy and Mizrahi to board; Oct 20 annual meeting set

  George Gaines (retired) and Jonathan Wheeler (health reasons) resigned as directors effective Sept 17/20, 2021.

• August 4, 2021, 7:59 PM ET other materiality 0.25 neutral item 5.02item 9.01

  Cryo-Cell signs new employment agreement with CIO Oleg Mikulinsky; $300K salary, $35K signing bonus

  Effective Aug 1, 2021, Cryo-Cell entered a 2-year employment agreement with CIO Oleg Mikulinsky.

• July 19, 2021, 7:59 PM ET earnings materiality 0.65 neutral item 2.02item 9.01

  Cryo-Cell Q2 fiscal 2021 revenue down 8% to $7.21M; net income rises to $1.17M

  Revenue $7.21M, down 8% from $7.87M; processing/storage fees $7.16M.

Executive changes

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.85 · Median 0.50 · Most common event other

3 positive 7 negative 19 neutral

source · CCEL on sec.gov